A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of Baricitinib in Patients With Diabetic Kidney Disease

This is a dose ranging study to evaluate the safety and efficacy of baricitinib in the treatment of participants with mild to moderate diabetic kidney disease.

Inclusion Criteria:

• Participants with Type 2 diabetes treated with at least one antihyperglycemic medicine for 12 months
• Have diabetic kidney disease and receiving one of two specific medicines used to treat high blood pressure or diabetic kidney disease for at least 3 months
• Estimated Glomerular Filtration Rate (eGFR) of 25 to 70 milliliter per minute per 1.73 square meter (mL/min/1.73 m²) (as determined by the Chronic Kidney Disease Epidemiology Collaboration equation) and a urinary albumin/creatinine ratio (UACR) >300 milligram per gram (mg/g) and <5000 mg/g

Exclusion Criteria:

• Too high blood pressure when you enter the study
• Some specific medicines used to treat high blood pressure or diabetic kidney disease
• Frequent high blood glucose levels
• Renal transplant or past history of dialysis
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Had a special X-ray in the past 30 days which involved also receiving an injection of dye into the vein
• Major surgery within 8 weeks of study entry or will require major surgery during the study
• Some types of vaccination
• Shingles or currently have symptoms of a cold sore
• Serious viral, bacterial, fungal, or parasitic infection, or a urinary infection, Tuberculosis (TB)
• Human immunodeficiency virus (HIV) infection- the virus that causes Acquired immunodeficiency syndrome (AIDS)
• Have or had some blood disorders, enlarged lymph glands or spleen, or some cancers.
• Serious circulatory, breathing, liver, stomach or bowel problems, neurological or psychiatric disorders
• Heart attack or heart failure, or a stroke
• Other serious disorders or illnesses
• Electrocardiogram (ECG) heart trace abnormalities
• Alcohol or illegal drug abuse
• Donated more than 500 mL of blood in the last 30 days (no blood donations allowed during the study)
• Pregnant or breastfeeding